CONMED repurchases $645M of 2.25% convertible notes due 2027 for $637M cash

CONMED Corp

Principle amount of $645.2M at 2.25% coupon due 2027 acquired for $637.2M in cash.
Closing expected June 15, 2026, subject to customary conditions.
Deal reduces outstanding convertible debt and potential future dilution.
Repurchases conducted through privately negotiated agreements with certain holders.
Company retains J. Wood Capital Advisors as advisor for the transaction.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

CONMED Corp entered into Purchase Agreements with certain holders of its 2.25% Convertible Senior Notes due 2027 valued at approximately $645.2 million aggregate principal amount of Notes from the holders thereof for approx (effective 2026-06-03).

Action: entry
Agreement: notes offering
Counterparty: certain holders of its 2.25% Convertible Senior Notes due 2027
Value: approximately $645.2 million aggregate principal amount of Notes from the holders thereof for approx
Effective: 2026-06-03

Exact text from the filing

On June 3, 2026, CONMED Corporation, a Delaware corporation (“ CONMED ”), entered into separate, privately negotiated purchase agreements (the “ Purchase Agreements ”) with certain holders of its 2.25% Convertible Senior Notes due 2027 (the “ Notes ”). Under the terms of the Purchase Agreements, the Company agreed to purchase approximately $645.2 million aggregate principal amount of Notes from the holders thereof for approximately $637.2 million in cash.

View on SEC.gov

801 material agreements filed in the last 30 days. Browse all material agreements →

CONMED Corp filing history →

Source: SEC EDGAR

accession 0001174947-26-000639

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.